Wilmington, Delaware, United States, May 09, 2023 (GLOBE NEWSWIRE) -- The global viral vector production market stood at USD 16.7 Bn in 2022 and is anticipated to exceed USD 17.3 Bn by 2031, expanding ...

The viral vector production market size was valued at $1.1 billion in 2022, and is estimated to reach $6.1 billion by 2032, growing at a CAGR of 18.8% from 2023 to 2032. Briefly introduce the concept ...

Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The "Viral Vector Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...

Rise in demand for adeno-associated virus vector types is driving the viral vector production market Increase in demand for downstream processing workflow is propelling the market WILMINGTON, Del., ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...

The use of engineered viruses to deliver transgenes for therapeutic effect is wide-ranging. Contemporary gene therapy vectors based on RNA viruses such as γ-Retroviruses and Lentiviruses 1,2, and DNA ...